← 홈

Antibody

112개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 112개
AntibodystaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleNovartisPhase 3

OFATUMUMAB + DHAP (OFATUMUMAB + DHAP)

Lymphoma, Large-Cell, Diffuse · Lymphoma, Large-Cell, Diffuse

#LymphomaLarge-CellDiffuse#Antibody#Phase3#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

G (Obinutuzumab, Obinutuzumab (G))

B-Cell Lymphoma; Non-Hodgkin Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone (Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone)

Newly Diagnosed Diffuse Large B-cell Lymphoma · Newly Diagnosed Diffuse Large B-cell Lym

#NewlyDiagnosedDiffuseLargeB-cell#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Pegylated Liposomal Doxorubicin (Doxil, Pegylated Liposomal Doxorubicin, Pegylated Liposomal Doxorubicin (Doxil) and Rituximab)

Non-Hodgkin's Lymphoma; Burkitt Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleGerman High-Grade Non-Hodgkin's…Phase 3

R-CHOEP 14 with 12x Rituximab (R-CHOEP 14 with 12x Rituximab)

Non-Hodgkin's Lymphoma (NHL) · Non-Hodgkin's Lymphoma (NHL)

#Non-HodgkinsLymphomaNHL#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Recombinant Human Interleukin-2 and Rituximab (Recombinant Human Interleukin-2 and Rituximab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#항체#면역항체+4
효능 ORR 100%임상시험 1상태 DISCONTINUED
AntibodystaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 1

Siplizumab (Siplizumab)

T-Cell Peripheral Lymphoma; Gamma Delta Hepatosplenic T-Cell Lymphoma · T-Cell Peripheral Lymphoma

#T-CellPeripheralLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Standard-dose Epirubicin Combined with CVP ± Rituximab (Standard-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleTianjin Medical University Canc…Phase 2

Tiselizumab (Tiselizumab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Tocilizumab at emerging CRS (Tocilizumab at emerging CRS)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodyBiologicstaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE

4 / 6 페이지

← 이전다음 →